Journal article
A Prospective, Open-Label Pilot Study of Concurrent Male Partner Treatment for Bacterial Vaginosis
EL Plummer, LA Vodstrcil, M Doyle, JA Danielewski, GL Murray, G Fehler, CK Fairley, DM Bulach, SM Garland, EPF Chow, JS Hocking, CS Bradshaw
Mbio | Published : 2021
Abstract
Up to 50% of women receiving first-line antibiotics for bacterial vaginosis (BV) experience recurrence within 12 weeks. Evidence suggests that reinfection from an untreated regular sexual partner contributes to recurrence. We conducted a pilot study of 34 heterosexual couples to describe the impact of concurrent partner treatment on the composition of the genital microbiota over a 12-week period. We also determined the acceptability and tolerability of concurrent partner treatment and obtained preliminary estimates of the efficacy of the intervention to inform a randomized controlled trial (RCT). Women received first-line antibiotic treatment for BV (i.e., oral metronidazole or intravaginal ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
E.L.P. was supported by an Australian Government Research Training Program (RTP) scholarship. C.S.B., C.K.F., and S.M.G. are supported by Australian NHMRC Leadership Investigator grants (GNT1173361, GNT1172900, and GNT1197951, respectively) . E.P.F.C. is supported by an Australian NHMRC Emerging Leadership Investigator grant (GNT1172873) . We acknowledge and thank Colette McGuinness, Marti Kaiser, and Karen Worthington for their assistance with recruitment and clinicians at MSHC for their referrals to the study staff. We also thank the couples that participated in the study. We declare no conflicts of interest for this project.